PharmaCyte Biotech, Inc.
PMCB
$0.94
$0.044.34%
NASDAQ
| 10/31/2025 | 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -25.03% | -33.79% | -35.56% | -30.08% | -11.16% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -21.88% | -30.75% | -32.86% | -28.06% | -8.94% |
| Operating Income | 21.88% | 30.75% | 32.86% | 28.06% | 8.94% |
| Income Before Tax | -131.19% | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -131.19% | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -131.19% | -104.18% | 9,083.97% | 1,877.84% | 1,866.55% |
| EBIT | 21.88% | 30.75% | 32.86% | 28.06% | 8.94% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -257.78% | -148.80% | 267.83% | 172.47% | 199.60% |
| Normalized Basic EPS | -279.67% | -117.05% | 108.92% | 10,358.33% | 4,575.65% |
| EPS Diluted | -257.78% | -148.80% | 267.83% | 172.47% | 199.60% |
| Normalized Diluted EPS | -279.67% | -117.05% | 108.92% | 10,358.33% | 4,575.65% |
| Average Basic Shares Outstanding | -15.57% | -15.90% | -23.50% | -35.50% | -44.19% |
| Average Diluted Shares Outstanding | -15.57% | -15.90% | -23.50% | -35.50% | -44.19% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |